GBI Research’s latest report, ""A Global Hyperhidrosis Market Landscape Assessment: Trends, Forecasts and Opportunities in a Growing Market"" provides an in-depth assessment of the current trends in the global hyperhidrosis market, with a particular focus on primary axillary hyperhidrosis. This report also assesses the commercial landscape through multilevel analytics that include data split by stage of development, molecular target, molecule type and route of administration.
Hyperhidrosis is a chronic disorder of excessive sweating beyond thermoregulatory needs and environmental conditions. It commonly arises in childhood and adolescence, and can affect patients for many years. Most cases of hyperhidrosis involve areas of high eccrine (sweat gland) density, particularly the armpits, palms and soles, and less often the facial area. According to the International Hyperhidrosis Society (IHS), the global prevalence population of hyperhidrosis is 367 million. The US has the most hyperhidrosis cases among the major developed countries covered in this report. Hyperhidrosis occurs in men and women equally, and can present at any age.
A limited number of approved products are available to treat primary axillary hyperhidrosis. Anticholinergics, antiperspirants and other botulinum toxin products, which are currently used off-label to treat the condition, are major competitors for available approved products. Existing therapies for the treatment of primary axillary hyperhidrosis have the ability to slow down the symptoms of the disease, but are unable to provide a complete cure. Moreover, the primary axillary hyperhidrosis pipeline lacks novelty and is very weak in terms of number of molecules in the development.
The IHS recommends the use of approved medical device therapies as a permanent therapy for primary axillary hyperhidrosis. A shift from drug therapy to approved medical device therapy - which can provide a permanent cure for the disease - is likely to restrict the growth of the overall primary axillary hyperhidrosis drug market.
Results from GBI Research’s secondary research efforts have been integrated and amalgamated with our own analytical views to create a cohesive, insightful and objective assessment, examining the current state of the primary axillary hyperhidrosis therapy market and its future commercial prospects. This new CBR report adds to our unique portfolio of trusted industry analyses that enable our clients to assess the promising commercial areas in the life sciences industry and exploit key business opportunities.
Primary axillary hyperhidrosis in the major developed markets will show a slight increase in growth rate during the forecast period
Key Reasons to Purchase
Table of Contents
Impact of Hyperhidrosis
Treatment Patterns and Management
Marketed Products and Competitive Assessment
Botox - Allergan (Approved)
Marketed Medical Devices and Competitive Assessment
miraDry - Miramar Labs
PrecisionTX - Cynosure
Unmet Needs and Gap Analysis
Pipeline by Stage of Development and Molecule Type
Pipeline by Route of Administration and Molecular Target
Market Size and Forecast (Global, US, Japan, UK, Germany, France, Spain and Italy)
Treatment Usage Pattern
Annual Cost of Therapy
Challenges for the Market Growth
Steps to Overcome Barriers
Make an enquiry before buying this Report
Please fill the enquiry form below.